超声造影与增强CT评估TACE治疗原发性肝癌疗效的价值对比

doi:10.3969/j.issn.1006-6233.2018.07.014

摘要
图/表
参考文献
相关文章 (5)

全文: PDF (1687 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的: 比较分析超声造影与增强CT对经导管肝动脉化疗栓塞术(TACE)治疗原发性肝癌疗效的评估价值。 方法: 以本院2015年1月至2017年12月行TACE治疗的70例原发性肝癌患者为研究对象,所有患者术后1个月行超声造影、增强CT及数字减影血管造影(DSA)检查,以DSA为金标准,比较超声造影、增强CT对TACE疗效评价的灵敏度、特异度及准确度。 结果: DSA复查显示病灶残留(阳性)63个,阴性31个;以DSA为金标准,超声造影诊断残留病灶(阳性)灵敏度、特异度、准确度分别为95.24%、100.00%、96.81%,增强CT诊断灵敏度、特异度、准确度分别为84.13%、100.00%、89.36%,超声造影诊断灵敏度、准确度均显著高于增强CT(P<0.05)。 结论: 相比增强CT,超声造影对原发性肝癌TACE治疗后病灶残留诊断灵敏度、准确度均显著高,为TACE治疗原发性肝癌疗效评估有效手段。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：超声造影, 增强CT, 经导管肝动脉化疗栓塞术, 原发性肝癌

Abstract：Objective: To comparatively analyze the value of contrast-enhanced ultrasound and enhanced CT in evaluating the curative effect of transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Methods: 70 patients with primary liver cancer treated by TACE in the hospital from January 2015 to December 2017 were selected as the subjects. All patients were examined by contrast-enhanced ultrasound, enhanced CT and digital subtraction angiography (DSA) at 1 month after operation. With DSA as the golden standard, the sensitivity, specificity and accuracy of contrast-enhanced ultrasound and enhanced CT in evaluating the curative effect of TACE were compared. Results: DSA showed 63 residual lesions (positive) and 31 negative lesions. With DSA as the golden standard, the sensitivity, specificity and accuracy of contrast-enhanced ultrasound in the diagnosis of residual lesions(positive) (95.24%,100.00%and 96.81%) were significantly higher than those of enhanced CT (84.13%,100.00%and 89.36%) (P<0.05). Conclusion: Compared with contrast-enhanced CT, the sensitivity and accuracy of contrast-enhanced ultrasound are significantly higher in diagnosing residual lesions after TACE for primary liver cancer. It is an effective method for evaluating the curative effect of TACE in the treatment of primary liver cancer.

Key words： Ultrasound contrast Enhanced CT Transcatheter arterial chemoembolization Primary carcinoma of liver

基金资助:四川省科技厅科技支撑计划项目,(编号:2015FZ0073)

引用本文:

王曦, 李东, 何芬, 邓旦, 徐丹. 超声造影与增强CT评估TACE治疗原发性肝癌疗效的价值对比[J]. 河北医学, 2018, 24(7): 1113-1116.
WANG Xi, LI Dong, HE Fen, et al. Contrastive Analysis of Contrast-enhanced Ultrasound and Enhanced CT in Evaluating the Efficacy of TACE in the treatment of Primary Liver Cancer. HeBei Med, 2018, 24(7): 1113-1116.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2018.07.014 或 http://www.hbyxzzs.cn/CN/Y2018/V24/I7/1113

[1] Feng MU,Schipper MJ,Balter JM,et al.A phase 2 trial of individualized adaptive stereotactic body radiation therapy(SBRT)for patients at high risk for liver damage[J].Int Radiat Oncol Biol Phys,2013,87(2):s27.
[2] Hennedige T,Venkatesh S K.Imaging of hepatocellular carcinoma:diagnosis,staging and treatment monitoring[J].Cancer Imaging,2013,12(3):530~547.
[3] 陈刚,唐晓军,魏强,等.超声造影评价肝动脉化疗栓塞联合微波消融治疗中晚期肝癌疗效[J].东南国防医药,2016,18(5):531~533,539.
[4] 乔彬彬,虞希祥,王舒婷,等.TACE术中灌注氟尿嘧啶、奥沙利铂及吡柔比星治疗原发性肝癌的临床效果分析[J].介入放射学杂志,2015,24(4):349~353.
[5] 敖劲,曾令雯,刘衡,等.原发性肝癌DSA表现与TACE疗效的关系分析[J].中国普通外科杂志,2016,25(1):51~56.
[6] 张大福,李振辉,杨光军,等.新型双能CT融合技术对肝癌TACE术后的评估[J].中国临床医学影像杂志,2016,27(8):557~561.
[7] 孙伟,李忱瑞.CT对肝癌TACE术后疗效及其残灶活性的评估作用分析[J].中国CT和MRI杂志,2015,13(5):77~79,106.
[8] 曾春.DWI联合CT增强扫描在评估TACE治疗肝癌患者的临床价值[J].中国CT和MRI杂志,2016,14(4):80~83.
[9] 余炎,吕君,余祖江,等.四种影像学检查评价原发性肝癌患者介入治疗的疗效[J].实用肝脏病杂志,2017,20(2):199~202.
[10] 黄崑,刘艳君,王学梅,等.超声造影与增强CT在评价肝癌行TACE后疗效的对照研究[J].现代肿瘤医学,2015,23(18):2670~2672,2673.
[11] 贵传玲.超声造影技术对原发性肝癌介入治疗效果的评估价值[J].山东医药,2016,56(33):86~88.
[12] 王海军,程瑞洪,王朝晖,等.超声造影在肝动脉化疗栓塞术联合微波消融治疗肝癌效果评估中的应用[J].北华大学学报(自然科学版),2017,18(5):645~648.
[13] Liu G J,Wang W,Lu M D,et al.Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J].Liver Cancer,2015,4(4):241~252.
[14] 王金岩,乌日丽其,庞芳,等.实时超声造影应用于肝恶性肿瘤微创治疗的临床价值[J].疾病监测与控制,2015,9(1):51~52.